LYCOS RETRIEVER 
Pharmaceuticals: Cadence Pharmaceuticals
built 211 days ago
Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company currently has two Phase III product candidates in development, Acetavance(TM) (intravenous acetaminophen) for the treatment of acute pain and fever, and Omigard(TM) (omiganan pentahydrochloride 1% topical gel) for the prevention of catheter-related infections. For more information about Cadence's pipeline, visit www.cadencepharm.com.
Source:
SAN DIEGO, Oct. 25 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. announced today the initial public offering of 6,000,000 shares of common stock at a price of $9 per share. All shares are being offered by Cadence Pharmaceuticals. Cadence Pharmaceuticals' common stock will be listed on the NASDAQ Global Market under the trading symbol "CADX." Merrill Lynch & Co. acted as sole book-running manager and Deutsche Bank Securities Inc. acted as co-lead manager for the offering. In addition, Pacific Growth Equities, LLC and JMP Securities LLC acted as co-managers for the offering. Cadence Pharmaceuticals has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares to cover over-allotments, if any.
Source:
The presentation will be simultaneously webcast and can be accessed on Cadence Pharmaceuticals' website at www.cadencepharm.com in the Investor Relations section. A replay of the webcast will be available approximately three hours following the live webcasts and will be archived for 14 days.
Source:
MORE ABOUT
Cadence Pharmaceuticals